Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study 200170 rollover eltrombopag long-term treatment and safety
2013-001371-20Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP) and acute myeloid leukemia (AML), sponsored by GSK. Primary endpoint: Long-term safety of eltrombopag. Started Jul 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-001371-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001371-20.